Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tsutomu Hirano

Showing results (1-10 of 188) with videos related to

Pageof 19
Sort By:
Nihon Jinzo Gakkai Shi|December 3, 2013
[Abnormal lipoprotein metabolism in CKD]Tsutomu Hirano
Clinical and Experimental Nephrology|October 18, 2013
Abnormal lipoprotein metabolism in diabetic nephropathyTsutomu Hirano
Journal of Atherosclerosis and Thrombosis|May 31, 2021
Small Dense LDL Tied to Diabetic Retinopathy-Similarity to AtherosclerosisTsutomu Hirano
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|February 27, 2008
[Treatment of lipid metabolism abnormalities with consideration given to renal protection]Tsutomu Hirano
JACC. Asia|August 7, 2025
Residual Risk for Carotid Atherosclerosis Within Normal LDL-C LevelsTsutomu Hirano
Diabetology International|July 3, 2023
Hypertriglyceridemia contributes significantly to high prevalence of small dense LDL-cholesterol in patients with type 2 diabetes, even when LDL-C targets are achievedTsutomu Hirano
Journal of Atherosclerosis and Thrombosis|July 13, 2018
Pathophysiology of Diabetic DyslipidemiaTsutomu Hirano
Rinsho Byori. the Japanese Journal of Clinical Pathology|June 28, 2007
[Metabolic syndrome and small dense LDL-cholesterol]Tsutomu Hirano
Journal of Atherosclerosis and Thrombosis|December 27, 2021
Residual Risk Still Remains in Low-Density LipoproteinTsutomu Hirano
Journal of Atherosclerosis and Thrombosis|September 4, 2024
Excess Triglycerides in Very Low-Density Lipoprotein (VLDL) Estimated from VLDL-Cholesterol could be a Useful Biomarker of Metabolic Dysfunction Associated Steatotic Liver Disease in Patients with Type 2 DiabetesTsutomu Hirano
Pageof 19

Showing results (1-10 of 188) with videos related to

Sort By:
Pageof 19
Nihon Jinzo Gakkai Shi|December 3, 2013
[Abnormal lipoprotein metabolism in CKD]Tsutomu Hirano
Clinical and Experimental Nephrology|October 18, 2013
Abnormal lipoprotein metabolism in diabetic nephropathyTsutomu Hirano
Journal of Atherosclerosis and Thrombosis|May 31, 2021
Small Dense LDL Tied to Diabetic Retinopathy-Similarity to AtherosclerosisTsutomu Hirano
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|February 27, 2008
[Treatment of lipid metabolism abnormalities with consideration given to renal protection]Tsutomu Hirano
JACC. Asia|August 7, 2025
Residual Risk for Carotid Atherosclerosis Within Normal LDL-C LevelsTsutomu Hirano
Diabetology International|July 3, 2023
Hypertriglyceridemia contributes significantly to high prevalence of small dense LDL-cholesterol in patients with type 2 diabetes, even when LDL-C targets are achievedTsutomu Hirano
Journal of Atherosclerosis and Thrombosis|July 13, 2018
Pathophysiology of Diabetic DyslipidemiaTsutomu Hirano
Rinsho Byori. the Japanese Journal of Clinical Pathology|June 28, 2007
[Metabolic syndrome and small dense LDL-cholesterol]Tsutomu Hirano
Journal of Atherosclerosis and Thrombosis|December 27, 2021
Residual Risk Still Remains in Low-Density LipoproteinTsutomu Hirano
Journal of Atherosclerosis and Thrombosis|September 4, 2024
Excess Triglycerides in Very Low-Density Lipoprotein (VLDL) Estimated from VLDL-Cholesterol could be a Useful Biomarker of Metabolic Dysfunction Associated Steatotic Liver Disease in Patients with Type 2 DiabetesTsutomu Hirano
Pageof 19